Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374637 | 1.00 | ADRA2A (0.38) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL8009084 | 1.00 | ADRA2A (0.38) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL7610062 | 1.00 | ADRA2A (0.38) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL8996674 | 0.98 | ADRA2A (0.36) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL7611532 | 0.93 | MEN1 (0.37) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL27338495 | 0.81 | ADORA2B (0.47) | ADRA2ACNR2SMN1; SMN2ADORA2BKDM4E | |
| SCHEMBL8374647 | 0.81 | ADRA2A (0.37) | ADRA2ACNR2PTGER4LMNASMN1; SMN2 | |
| SCHEMBL8375311 | 0.81 | PTGER4 (0.44) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL8374665 | 0.81 | PTGER4 (0.44) | ADRA2ACNR2PTGER4PTGER1PTGER3 | |
| SCHEMBL7994402 | 0.80 | ACLY (0.33) | CNR2PTGER4PTGER1PTGER3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5670507-A | Method for reversing multiple drug resistant phenotype | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | disclosed |
| US-5837703-A | AUTOIMMUNE DISEASES, ARTHRITIS, CANCER, LEUKEMIA, MULTIPLE SCLEROSIS; ANTITUMOR AGENTS | CELL THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5824677-A | SUBSTITUTED WITH HETEROCYCLIC RING, ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE | CELL THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5777117-A | ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE, CYTOTOXIC AGENTS; MICROBIOCIDES, FUNGICIDES | CELL THERAPEUTICS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5750575-A | ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS; CYTOTOXIC AGENTS; MICROBIOCIDES; FUNGICIDES | CELL THERAPEUTICS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5670507-A | Method for reversing multiple drug resistant phenotype | CELL THERAPEUTICS, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5641783-A | ANTIINFLAMMATORY OR IMMUNOSUPPRESSIVE AGENTS | CELL THERAPEUTICS, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| EP-0719267-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | disclosed |
| US-5470878-A | Cell signaling inhibitors | CELL THERAPEUTICS, INC. (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | disclosed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |